EMA Authorised: Orfadin (nitisinone) — Swedish Orphan Biovitrum International AB

View source ↗

Summary

The European Medicines Agency authorised Orfadin (nitisinone) by Swedish Orphan Biovitrum International AB for hereditary tyrosinemia type I, with decision date…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Tyrosinemia Type

Drugs mentioned

• Orfadin (nitisinone)

Snippet

Status: Authorised. Therapeutic area: Tyrosinemias. MAH: Swedish Orphan Biovitrum International AB. Decision date: 03/07/2025